Fluorescence Guided Surgery Systems Market Segmentation:
Application (Cancer Surgery, Neurosurgery, Ophthalmic Surgery, Cardiac Surgery)
The cancer surgery segment is anticipated to dominate the fluorescence guided surgery systems market with a share of 63.4% during the forecast period. The growing incidences of cancer and fatalities across the world are creating a surge in new and more effective treatment methods. According to a report published by WHO, in February 2024, the estimated number of new cancer and related death cases reached 20 million and 9.7 million respectively in 2022. The total amount of new cases was followed by 2.5 million lung cancer, 2.3 million breast cancer, 1.9 million colorectal cancer, 1.5 million prostate cancer, and 0.9 million stomach cancer. Thus, FGS has become a revolutionary technique in the surgical world for treating such chronic diseases, driving growth in this segment.
Type (Radioactive Tracers, Near-Infrared (NIR) Tracers, Visible Light Tracers)
In terms of type, the radioactive tracers segment is estimated to hold a significant share of the fluorescence guided surgery systems market by the end of 2035. The growth in this segment is attributed to the rising demand for minimally invasive procedures such as Laparoscopy and technological advancements in surgical imaging techniques such as robotic surgery. The radioactive tracers are capable of transmitting signals even from deeper layers of tissue, making them preferable for precise lesion localization. Such abilities are further driving demand in this segment due to fewer challenges and better patient outcomes during operations.
Our in-depth analysis of the fluorescence guided surgery systems market includes the following segments:
|
Application |
|
|
Type |
|
|
End use |
|
|
Imaging Modalities |
|
|
Target Population |
|
